CRISPR Therapeutics CRSP Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's operating income?
- CRISPR Therapeutics (CRSP) reported operating income of -$130.25M in Q1 2026.
- How has CRISPR Therapeutics's operating income changed year-over-year?
- CRISPR Therapeutics's operating income increased by 12.2% year-over-year, from -$148.42M to -$130.25M.
- What is the long-term trend for CRISPR Therapeutics's operating income?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's operating income has grown at a -0.6% compound annual growth rate (CAGR), from -$673.16M to -$664.57M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.